Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Chi

Showing results (191-200 of 410) with videos related to

Pageof 41
Sort By:
ACS Pharmacology & Translational Science|April 8, 2020
Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted TherapiesJon K Obst, Jun Wang, Kunzhong Jian, et al.
Future Oncology (London, England)|August 20, 2024
Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studiesLawrence I Karsh, Katherine B Bevans, Fred Saad, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2010
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancerSrikala S Sridhar, Christina M Canil, Kim N Chi, et al.
The New England Journal of Medicine|October 8, 2004
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerIan F Tannock, Ronald de Wit, William R Berry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium studySridharan Gururangan, Susan N Chi, Tina Young Poussaint, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 19, 2015
The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)Fred Saad, Kim N Chi, Antonio Finelli, et al.
Current Oncology (Toronto, Ont.)|March 27, 2024
<sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical PracticeKim N Chi, Steven M Yip, Glenn Bauman, et al.
Journal of Pediatric Hematology/Oncology|November 12, 2005
A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancerMark W Kieran, Christopher D Turner, Joshua B Rubin, et al.
Small (Weinheim an Der Bergstrasse, Germany)|February 27, 2016
Continuous Flow Deformability-Based Separation of Circulating Tumor Cells Using Microfluidic RatchetsEmily S Park, Chao Jin, Quan Guo, et al.
Clinical Genitourinary Cancer|February 13, 2020
Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell CarcinomaJack V W Bacon, Matti Annala, Maryam Soleimani, et al.
Pageof 41

Showing results (191-200 of 410) with videos related to

Sort By:
Pageof 41
ACS Pharmacology & Translational Science|April 8, 2020
Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted TherapiesJon K Obst, Jun Wang, Kunzhong Jian, et al.
Future Oncology (London, England)|August 20, 2024
Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studiesLawrence I Karsh, Katherine B Bevans, Fred Saad, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2010
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancerSrikala S Sridhar, Christina M Canil, Kim N Chi, et al.
The New England Journal of Medicine|October 8, 2004
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerIan F Tannock, Ronald de Wit, William R Berry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium studySridharan Gururangan, Susan N Chi, Tina Young Poussaint, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 19, 2015
The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)Fred Saad, Kim N Chi, Antonio Finelli, et al.
Current Oncology (Toronto, Ont.)|March 27, 2024
<sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical PracticeKim N Chi, Steven M Yip, Glenn Bauman, et al.
Journal of Pediatric Hematology/Oncology|November 12, 2005
A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancerMark W Kieran, Christopher D Turner, Joshua B Rubin, et al.
Small (Weinheim an Der Bergstrasse, Germany)|February 27, 2016
Continuous Flow Deformability-Based Separation of Circulating Tumor Cells Using Microfluidic RatchetsEmily S Park, Chao Jin, Quan Guo, et al.
Clinical Genitourinary Cancer|February 13, 2020
Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell CarcinomaJack V W Bacon, Matti Annala, Maryam Soleimani, et al.
Pageof 41